Alper SEYHAN, Kenan SOFUOĞLU, Merve Begüm OSMANLIOĞLU

Gnrh Agoist Uzun Protokol Tedavi Uygulanan Polikistik Over Sendromu Olan ve Olmayan Hastaların Gebelik Sonuçlarının Karşılaştırılması

Kadın infertilitesinin en sık nedeni ovulasyon bozukluklarıdır. Anovulatuar infertilitenin en temel nedeni Polikistik Over Sendromudur. Polikistik Over Sendromu fertil çağdaki kadınlarda görülen en sık endokrin bozukluktur. Polikistik Over Sendromlu infertil kişide ilk tercih ovulasyon indüksiyon ajanı Klomifen Sitrat’tır. Klomifen Sitrat’a yanıtsız olgularda eksojen gonadotropinler kullanılmaktadır. Çalışmamızda, GnRH Agonist Uzun Protokol uygulanan PKOS olan ve olmayan hastalarda gebelik sonuçları ve yanısıra kullanılan gonadotropin dozları, bazal FSH, E2, prolaktin değerleri, elde edilen matur oosit sayıları gibi parametreleri retrospektif olarak karşılaştırmayı hedefledik.

To Compare Pregnancy Results of Patients with Or Without PcosWho Are Included Gnrh Agonist Long Protocol Treatment

Ovulation defects are the most common cause of woman infertility. Polycystic Ovary Syndrome is main cause of anovulatory infertility and most commonly seen endocrine pathology in fertile period of women. In infertile patients with PCOS, first choice of induction agent is Klomifen Citrate. Patients who do not response to Klomifen Citrate, exogen gonadotropines are used for induction. In our study we aimed to evaluate gonadotrophine doses, basaline FSH, E2, prolactine levels, mature oocyte number and pregnancy rates in GnRH Agonist Long Protocol treatment in patients who have PCOS or not.

PDF

___

1. Azziz R, Woods KS, Reyna K, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89:2745-9.
2. Yildiz BO, Chang W, Azziz R. Polycystic ovary syndrome and ovulation induction. Minerva Ginecol 2003; 55:425-39
3. Adashi EY, Rock JA, Resonwacks Z, Reproductive endocrinology surgery and technology. 1996; chapter60: 1208-1223
4. Macklon NS, Fauser BCJM. Progress in ovarian stimulation. Ann. d'Endocrinol 1999; 60: 137-142.
5. Speroff L, Marc A. Fritz; Clinical Gyneacologic Endocrinology and İnfertility. Williams &Wilkins, Baltimore. 8. Edition,2010; 256-257
6. Diedrich K, Diedrich C, Santos E, Zoll C, al-Hasani S; Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation; Hum Reprod. 1994 May;9(5):788-91.
7. Borm G, Mannaerts B; Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group; Hum Reprod. 2000 Jul;15(7):1490-8
8. Fluker M, Grifo J, Leader A; Efficacy and safety of ganirelix acetate versus leuprolide acetate in undergoing controlled ovarian hyperstimulation; Fertil Steril. 2001 Jan;75(1):38-45
9. Lambalk CB, Banga FR, Huirne JA; GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type; Human Reproduction Update, Volume 23, Issue 5, 1 September 2017, Pages 560–579.
10. Griesinger G, Diedrich K, Tarlatzis BC, [et al.]. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: A meta-analysis. Reprod BioMed Online. 2006, 13 (5), 628–638.
11. Milan Trenkić, Jasmina Popović, Vesna Kopitović, Artur Bjelica, Radomir Živadinović, Sonja Pop-Trajković. Flexible GnRH antagonist protocol vs. long GnRH agonist protocol in patients with polycystic ovary syndrome treated for IVF: comparison of clinical outcome and embryo quality. Ginekol Pol 2016;87(4):265-270.